A private pharmaceutical company re-purposing an existing approved drug for a new indication. N-003 (ambrisentan) may be the first therapy for portal hypertension and its complications in patients with liver cirrhosis.
Location
-
Lange Gasse 15, 4052 Basel, Switzerland
Canton
Facts & figures
-
Type of organizationPrivate company
-
Year of foundation2010
-
Number of employees in Switzerland1-9
Core competencies
Keep browsing
You may also be interested in
Memorises Bio AG 
- R&D
Member
Pilatus Biosciences SA
- R&D
Member
Step Pharma SAS
- R&D
Member